Share-based Payment Arrangement, Expense of Xeris Biopharma Holdings, Inc. from 30 Sep 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Xeris Biopharma Holdings, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 31 Dec 2025.
  • Xeris Biopharma Holdings, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $5,272,000, a 47% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $22,366,000, a 22% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $22,366,000, a 22% increase from 2024.
  • Xeris Biopharma Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $18,363,000, a 71% increase from 2023.
  • Xeris Biopharma Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10,716,000, a 12% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Xeris Biopharma Holdings, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $22,366,000 $5,272,000 +$1,677,000 +47% 01 Oct 2025 31 Dec 2025 10-K 02 Mar 2026 2025 FY
Q3 2025 $20,689,000 $7,643,000 +$875,000 +13% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $19,814,000 $5,008,000 +$775,000 +18% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $19,039,000 $4,443,000 +$676,000 +18% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $18,363,000 $3,595,000 +$828,000 +30% 01 Oct 2024 31 Dec 2024 10-K 02 Mar 2026 2025 FY
Q3 2024 $17,535,000 $6,768,000 +$4,311,000 +175% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $13,224,000 $4,233,000 +$1,305,000 +45% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $11,919,000 $3,767,000 +$1,203,000 +47% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $10,716,000 $2,767,000 +$1,000 +0.04% 01 Oct 2023 31 Dec 2023 10-K 02 Mar 2026 2025 FY
Q3 2023 $10,715,000 $2,457,000 -$484,000 -16% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $11,199,000 $2,928,000 -$224,000 -7.1% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $11,423,000 $2,564,000 -$737,000 -22% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 FY
Q4 2022 $12,160,000 $2,766,000 +$23,000 +0.84% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2025 2024 FY
Q3 2022 $12,137,000 $2,941,000 -$724,000 -20% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $12,861,000 $3,152,000 +$640,000 +25% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 FY
Q1 2022 $12,221,000 $3,301,000 +$840,000 +34% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 FY
Q4 2021 $11,381,000 $2,743,000 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
Q3 2021 $3,665,000 +$1,611,000 +78% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $2,512,000 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $2,461,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q3 2020 $2,054,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3

Xeris Biopharma Holdings, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $22,366,000 +$4,003,000 +22% 01 Jan 2025 31 Dec 2025 10-K 02 Mar 2026 2025 FY
2024 $18,363,000 +$7,647,000 +71% 01 Jan 2024 31 Dec 2024 10-K 02 Mar 2026 2025 FY
2023 $10,716,000 -$1,444,000 -12% 01 Jan 2023 31 Dec 2023 10-K 02 Mar 2026 2025 FY
2022 $12,160,000 +$779,000 +6.8% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2025 2024 FY
2021 $11,381,000 +$3,108,000 +38% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
2020 $8,273,000 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.